Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2016

21.09.2016 | Brief Report

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

verfasst von: Vakaramoko Diaby, Georges Adunlin, Askal A. Ali, Simon B. Zeichner, Gilberto de Lima Lopes, Christine G. Kohn, Alberto J. Montero

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC).

Patients and methods

We constructed a Markov model to assess the cost-effectiveness of four different HER2 targeted treatment sequences in patients with HER2-positive mBC treated in the U.S. The model followed patients weekly over their remaining life expectancies. Health states considered were progression-free survival (PFS) 1st to 3rd lines, and death. Transitional probabilities were based on published phase III trials. Cost data (2015 US dollars) were captured from the U.S. Centers for Medicare and Medicaid Services (CMS) drug payment table and physician fee schedule. Health utility data were extracted from published studies. The outcomes considered were PFS, OS, costs, QALYs, the incremental cost per QALY gained ratio, and the net monetary benefit. Deterministic and probabilistic sensitivity analyses assessed the uncertainty around key model parameters and their joint impact on the base-case results.

Results

The combination of trastuzumab, pertuzumab, and docetaxel (THP) as first-line therapy, trastuzumab emtansine (T-DM1) as second-line therapy, and lapatinib/capecitabine third-line resulted in 1.81 QALYs, at a cost of $335,231.35. The combination of trastuzumab/docetaxel as first line without subsequent T-DM1 or pertuzumab yielded 1.41 QALYs, at a cost of $175,240.69. The least clinically effective sequence (1.27 QALYs), but most cost-effective at a total cost of $149,250.19, was trastuzumab/docetaxel as first-line therapy, T-DM1 as second-line therapy, and trastuzumab/lapatinib as third-line therapy.

Conclusion

Our results suggest that THP as first-line therapy, followed by T-DM1 as second-line therapy, would require at least a 50 % reduction in the total drug acquisition cost for it to be considered a cost-effective strategy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32CrossRef Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32CrossRef
2.
Zurück zum Zitat John M, Hinke A, Stauch M et al (2012) Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines–a phase II multipractice study. BMC Cancer 12:165CrossRefPubMedPubMedCentral John M, Hinke A, Stauch M et al (2012) Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines–a phase II multipractice study. BMC Cancer 12:165CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099CrossRefPubMed Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099CrossRefPubMed
4.
Zurück zum Zitat Cameron D, Casey M, Oliva C et al (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–934CrossRefPubMedPubMedCentral Cameron D, Casey M, Oliva C et al (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–934CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMed Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMed
6.
Zurück zum Zitat Swain S, Kim S, Cortes J (2014) Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 350 Swain S, Kim S, Cortes J (2014) Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 350
7.
Zurück zum Zitat National Comprehensive Cancer Network (2015) NCCN clinical practice guidelines in oncology: breast cancer. Version 3. National Comprehensive Cancer Network (2015) NCCN clinical practice guidelines in oncology: breast cancer. Version 3.
8.
Zurück zum Zitat Durkee BY, Qian Y, Pollom EL et al (2015) Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol 2015(62):9105 Durkee BY, Qian Y, Pollom EL et al (2015) Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol 2015(62):9105
9.
Zurück zum Zitat Swain SM, Kim S, Cortés J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471CrossRefPubMedPubMedCentral Swain SM, Kim S, Cortés J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791CrossRefPubMed Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791CrossRefPubMed
11.
Zurück zum Zitat Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130CrossRefPubMed Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130CrossRefPubMed
12.
Zurück zum Zitat von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999–2006CrossRef von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999–2006CrossRef
13.
Zurück zum Zitat Sorensen SV, Goh JW, Pan F et al (2012) Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care 28:12–21CrossRefPubMed Sorensen SV, Goh JW, Pan F et al (2012) Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care 28:12–21CrossRefPubMed
14.
Zurück zum Zitat Gray AM, Clarke PM, Wolstenholme JL et al (2010) Applied methods of cost-effectiveness analysis in healthcare. Oxford University Press, Oxford Gray AM, Clarke PM, Wolstenholme JL et al (2010) Applied methods of cost-effectiveness analysis in healthcare. Oxford University Press, Oxford
15.
Zurück zum Zitat Laupacis A, Feeny D, Detsky AS et al (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473–481PubMedPubMedCentral Laupacis A, Feeny D, Detsky AS et al (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473–481PubMedPubMedCentral
16.
Zurück zum Zitat Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371:796–797CrossRefPubMed Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371:796–797CrossRefPubMed
17.
Zurück zum Zitat Winkelmayer WC, Weinstein MC, Mittleman MA et al (2002) Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22:417–430CrossRefPubMed Winkelmayer WC, Weinstein MC, Mittleman MA et al (2002) Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22:417–430CrossRefPubMed
18.
Zurück zum Zitat Lee CP, Chertow GM, Zenios SA (2009) An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value in Health 12:80–87CrossRefPubMed Lee CP, Chertow GM, Zenios SA (2009) An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value in Health 12:80–87CrossRefPubMed
19.
Zurück zum Zitat Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRefPubMed Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRefPubMed
20.
Zurück zum Zitat Guyot P, Ades AE, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9-2288-12-9 Guyot P, Ades AE, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9-2288-12-9
21.
Zurück zum Zitat Diaby V, Ali AA, Adunlin G et al (2016) Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin 32(6):991–996CrossRefPubMed Diaby V, Ali AA, Adunlin G et al (2016) Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin 32(6):991–996CrossRefPubMed
24.
Zurück zum Zitat Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2:859–866PubMedPubMedCentral Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2:859–866PubMedPubMedCentral
25.
Zurück zum Zitat Niraula S, Amir E, Vera-Badillo F et al (2014) Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32:3634–3642CrossRefPubMed Niraula S, Amir E, Vera-Badillo F et al (2014) Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32:3634–3642CrossRefPubMed
26.
Zurück zum Zitat Garrison LP, Lubeck D, Lalla D et al (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:489–498CrossRefPubMed Garrison LP, Lubeck D, Lalla D et al (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:489–498CrossRefPubMed
29.
Zurück zum Zitat Attard C, Brown S, Alloul K et al (2014) Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21:e41CrossRefPubMedPubMedCentral Attard C, Brown S, Alloul K et al (2014) Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21:e41CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Doyle S, Lloyd A, Walker M (2008) Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62:374–380CrossRefPubMed Doyle S, Lloyd A, Walker M (2008) Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62:374–380CrossRefPubMed
32.
Zurück zum Zitat Evans DB, Hurley SF (1995) The application of economic evaluation techniques in the health sector: the state of the art. J Int Dev 7:503–524CrossRef Evans DB, Hurley SF (1995) The application of economic evaluation techniques in the health sector: the state of the art. J Int Dev 7:503–524CrossRef
33.
Zurück zum Zitat Gold M (1996) Cost-effectiveness in health and medicine. Oxford University Press, Oxford Gold M (1996) Cost-effectiveness in health and medicine. Oxford University Press, Oxford
34.
Zurück zum Zitat Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
35.
Zurück zum Zitat National Institute for Health and Care Excellence (2015) Final appraisal determination. Trastuzumab emtansine for treating HER2- positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. 2015 National Institute for Health and Care Excellence (2015) Final appraisal determination. Trastuzumab emtansine for treating HER2- positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. 2015
36.
Zurück zum Zitat Neumann PJ, Weinstein MC (2010) Legislating against use of cost-effectiveness information. N Engl J Med 363:1495–1497CrossRefPubMed Neumann PJ, Weinstein MC (2010) Legislating against use of cost-effectiveness information. N Engl J Med 363:1495–1497CrossRefPubMed
37.
Zurück zum Zitat Eddy DM, Hollingworth W, Caro JJ et al (2012) Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 32:733–743CrossRefPubMed Eddy DM, Hollingworth W, Caro JJ et al (2012) Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 32:733–743CrossRefPubMed
Metadaten
Titel
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
verfasst von
Vakaramoko Diaby
Georges Adunlin
Askal A. Ali
Simon B. Zeichner
Gilberto de Lima Lopes
Christine G. Kohn
Alberto J. Montero
Publikationsdatum
21.09.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3978-6

Weitere Artikel der Ausgabe 1/2016

Breast Cancer Research and Treatment 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.